Third View Private Wealth LLC Invests $1.21 Million in IDEXX Laboratories, Inc. $IDXX

Key Points

• Third View Private Wealth LLC established a new position in IDEXX by purchasing 1,782 shares valued at about $1.21 million in the fourth quarter.
• Insiders have been heavy sellers recently — the CEO sold 23,326 shares for roughly $15.34 million and insiders sold 45,957 shares totaling about $29.86 million in the last quarter, leaving insiders with 0.79% ownership.
• IDEXX beat quarterly expectations (EPS $3.08 vs. $2.93 est., revenue $1.09B vs. $1.07B), reported 14.3% revenue growth year-over-year, and set FY2026 EPS guidance of 14.29–14.80, with analysts holding a consensus "Moderate Buy" and a $772.22 price target.

Third View Private Wealth LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,782 shares of the company's stock, valued at approximately $1,206,000.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company's stock worth $397,000 after buying an additional 15 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company's stock valued at $243,000 after buying an additional 16 shares during the period. Moss Adams Wealth Advisors LLC grew its position in IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company's stock valued at $337,000 after buying an additional 17 shares during the period. CWA Asset Management Group LLC grew its position in IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company's stock valued at $344,000 after buying an additional 17 shares during the period. Finally, Private Trust Co. NA grew its position in IDEXX Laboratories by 9.4% during the third quarter. Private Trust Co. NA now owns 209 shares of the company's stock valued at $134,000 after buying an additional 18 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 1,464 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares of the company's stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX opened at $574.00 on Tuesday. The firm has a market cap of $45.59 billion, a P/E ratio of 43.92, a PEG ratio of 3.42 and a beta of 1.72. IDEXX Laboratories, Inc. has a 1-year low of $391.05 and a 1-year high of $769.98. The company has a 50 day simple moving average of $606.09 and a two-hundred day simple moving average of $656.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company's revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research report on Monday, February 9th. UBS Group cut their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research report on Tuesday, February 3rd. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $772.22.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.